Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / France

European Innovation Council · Running

TAFALGIE The first in-class non-opioid drug for treating moderate, severe, and persistent pain with no addiction nor tolerance

Coordinator
Tafalgie Therapeutics, France
Runs
1 March 2024 to 30 November 2026
Status
Running
EU funding
€2.5m
Total cost
€17.4m
Partners
1 organisations in 1 countries
Type
European Innovation Council
Grant agreement
101145380

What the project is doing

In the project's own words, from its summary on CORDIS.

Tafalgie Therapeutics is a biopharmaceutical research company developing a new scientific approach for next-generation treatments, based on a true breakthrough innovation derived from the mechanism of action of an endogenous protein modulating the pain signal. Our ambition: to become the reference player in the field of pain medication by designing and proposing new active pharmaceutical ingredients for non-opioid analgesics, in a context marked by the opioid crisis, through the development of first-in-class polypeptides derived from TAFA4 and its peptide derivatives.

We aim to develop and bring to patients more effective, well-tolerated, non-addictive, long-term treatments for the relief of acute pain - mild, moderate, and severe -, as well as for the prevention of chronic pain.

Topics

Who is involved

OrganisationCityCountryRole
Tafalgie TherapeuticsMarseilleFranceCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI